



# ● Reliable prevention. Less stress.

## Nobivac<sup>®</sup> Intra-Trac<sup>®</sup> Oral Bb

### Nobivac<sup>®</sup> Intra-Trac<sup>®</sup> Oral Bb delivers convenience that works.

For social dogs and puppies, Nobivac<sup>®</sup> Intra-Trac<sup>®</sup> Oral Bb was shown to be effective against canine infectious tracheobronchitis caused by *Bordetella bronchiseptica* (Bb).<sup>1</sup>

- Easy to administer in the buccal cavity
- Syringes with a green plunger provided to differentiate from injectable vaccines
- No booster required for primary immunization
- For use in dogs seven weeks of age or older

### SIGNIFICANT PROTECTION

21-day efficacy challenge data study results<sup>1</sup>:

- Significantly reduced duration of coughing and shedding of Bb in vaccinates compared with control dogs

### PROVEN TO BE SAFE

- In a field safety trial that included over 300 dogs, there were no adverse events deemed related to Nobivac<sup>®</sup> Intra-Trac<sup>®</sup> Oral Bb<sup>1</sup>



WITH COMFORT IN MIND, CHOOSE NOBIVAC<sup>®</sup> INTRA-TRAC<sup>®</sup> ORAL Bb.

To learn more, contact your Merck Animal Health sales representative or your distributor representative.

**Customer Service:** 1-800-521-5767  
(Monday–Friday, 9:00AM–6:00PM EST)

**Technical Services:** 1-800-224-5318  
(Monday–Friday, 8:30AM–7:00PM EST)

**Nobivac<sup>®</sup>**  
Protection unites us.

Reference: 1. Summary of studies supporting USDA product licensure for Nobivac Intra-Trac Oral Bb. USDA website. Available at: [www.aphis.usda.gov/aphis/ourfocus/animalhealth/veterinary-biologics/product-summaries/vet-label-data/83c6706d-ffd8-4e32-ba7a-706e1bcb9333](http://www.aphis.usda.gov/aphis/ourfocus/animalhealth/veterinary-biologics/product-summaries/vet-label-data/83c6706d-ffd8-4e32-ba7a-706e1bcb9333). Accessed October 28, 2020.

Copyright © 2021 Intervet Inc., d/b/a Merck Animal Health, a subsidiary of Merck & Co., Inc. All rights reserved. US-NOV-201000025 234416





## VACCINATION STATION

# Canine Parainfluenza Virus Vaccination

Amy E. S. Stone, DVM, PhD  
University of Florida College of Veterinary Medicine

**SNOWBALL EFFECT**  
Canine parainfluenza virus can have a significant impact on young or vulnerable dogs when it interacts with other pathogens.

Canine parainfluenza virus (CPIV) is a highly contagious ribonucleic acid virus that causes respiratory disease in dogs worldwide. It is an important agent in the canine infectious respiratory disease (CIRD) complex (also known as kennel cough), which is spread by dogs in group housing, social situations, and, sometimes, veterinary hospitals. Although considered a noncore vaccine, CPIV can play a role in exacerbating other respiratory infections, and vaccination of at-risk dogs may help promote herd immunity.

## CANINE PARAINFLUENZA VIRUS OVERVIEW

Dogs with CPIV may exhibit no clinical signs or mild clinical signs of a dry, harsh cough for up to 7 days, with or without fever and nasal discharge.<sup>1</sup> These clinical signs may become much more severe in dogs with viral or bacterial coinfections (**FIGURE 1**).<sup>2</sup> Additionally, because CPIV suppresses the innate branch of the immune system and causes the loss of cilia and ciliated epithelium, it makes conditions more favorable for coinfections.<sup>3</sup> In puppies or immunosuppressed adult dogs, the presence of CPIV in coinfections can lead to a more severe pneumonia and can be fatal.<sup>3,4</sup>

Transmission of CPIV is mostly through aerosols and fomites.<sup>5</sup> The incubation period for CPIV is 3 to 10 days after infection, and viral shedding typically occurs 6 to 8 days after infection.<sup>5</sup> Because dogs with CPIV can be asymptomatic, they may shed virus without showing clinical signs. Before the development of CPIV vaccines, CPIV could be isolated from up to



**FIGURE 1.** Dog with complicated canine infectious respiratory disease and mucoid nasal discharge.

CIRD outbreaks can be prevented with a multifaceted approach that involves population control, priority handling, surface disinfection, and vaccination.

50% of dogs with respiratory disease in group housing situations.<sup>6</sup>

Coinfection with multiple pathogens is common in CIRD. The agents of CIRD can act successively or synergistically to cause respiratory illness. In the past, the common agents associated with CIRD were CPIV, canine adenovirus type 2, and *Bordetella bronchiseptica*. Later, canine herpesvirus-1 and canine influenza virus (H3N8 and H3N2) were added to the list of reported agents. More recent advances in identification methods have discovered other pathogens that may play a role in CIRD, and the list continues to grow (TABLE 1).<sup>7</sup> The prevalence of these pathogens and the roles that they play in the coinfection process have not yet been well studied.<sup>8</sup>

Outbreaks of CIRD involving CPIV have been reported around the world. When large numbers of dogs are housed together or commingle (e.g., rescue settings, boarding facilities, shelters, daycare facilities), they are more likely to develop clinical signs of CIRD. Clinical signs of CIRD also become more likely the longer dogs stay in these situations.<sup>9</sup> CPIV survives on nonporous surfaces for 4 to 12 days; however, it is susceptible to a range of disinfectants.<sup>4</sup> CIRD outbreaks can be prevented with a multifaceted approach that involves population control, priority handling, surface disinfection, and vaccination.

### IMPORTANCE OF VACCINATION

One goal of vaccination against any pathogen is to achieve or maintain herd immunity. If all animals in a population are susceptible to a highly contagious agent, such as CPIV, there is nothing to stop the spread of that agent. Vaccinating individual animals is intended to minimize clinical disease in those individuals and reduce agent shedding. The collective impact of immunizing many or most individuals is the deceleration or even halt of disease spread within the population (i.e., herd immunity).<sup>10</sup> This strategy protects the naïve or still-susceptible animals within the group.

Given the role that CPIV plays in many instances of CIRD, including exacerbating clinical disease in coinfections, preventing its spread is important in controlling respiratory disease in dogs. By vaccinating

**TABLE 1 Pathogens Associated With Canine Infectious Respiratory Disease Complex<sup>2,7,8</sup>**

PATHOGEN	VACCINE COMMERCIALY AVAILABLE?
Adenovirus-1	Yes
Distemper virus	Yes
Parainfluenza virus	Yes
Respiratory coronavirus	No
Influenza A virus (H3N8 + H3N2)	Yes
Herpesvirus-1	No
Pneumovirus	No
Hepacivirus	No
Reoviruses	No
<i>Bordetella bronchiseptica</i>	Yes
<i>Mycoplasma canis</i>	No
<i>Mycoplasma cynos</i>	No
<i>Streptococcus equi</i> subsp. <i>zooepidemicus</i>	No
<i>Chlamydophila psittaci</i>	No



as often as possible against CPIV (using multivalent vaccines), veterinarians can maximize herd immunity when dogs are housed together or commingle. Based on the ever-growing number of dog parks and daycare facilities, such interactions are increasing.<sup>11</sup>

Previously, the ratio of available vaccines to the agents responsible for CIRDC was thought to be much higher. With the discovery of more pathogens that may be involved in causing CIRDC, the proportion of ones with developed vaccines decreases (TABLE 1). Thus, it is critical that veterinarians vaccinate at-risk animals against the pathogens for which vaccinations exist to help control or prevent infection.

## AVAILABLE CANINE PARAINFLUENZA VIRUS VACCINES

Several vaccines against CPIV exist (TABLE 2). Most are incorporated in multivalent vaccines with other antigens. CPIV vaccines do not produce sterilizing immunity (i.e., complete prevention of viral replication); rather, they decrease the severity of clinical signs, the amount of virus, and the degree of viral shedding. These vaccines are relatively efficacious and safe. Their duration of immunity is unclear and is likely less than 3 years.<sup>12</sup> More research is needed on the efficacy and immune response to CPIV vaccination to further determine duration of immunity.<sup>3</sup>

### How the Vaccines Work

All the CPIV vaccines are attenuated live virus vaccines. They are designed to be administered either parenterally or intranasally.<sup>7</sup> CPIV is not stable in the oral environment; therefore, no oral vaccines against

CPIV exist. The parts of the immune response that they stimulate and the possible postvaccinal adverse events depend on the vaccine administration route.

Parenteral vaccination provokes a primarily adaptive, systemic IgG response. These responses are good at defending the body once an agent has invaded it. Mucosal (intranasal) vaccine administration stimulates the innate immune response—a local IgA response designed to prevent adherence and invasion of pathogens—as well as a low-level systemic IgG response.<sup>13,14</sup> When CPIV enters the body, it triggers both the mucosal and the systemic responses of the adaptive immune system. Therefore, it is reasonable to expect that both routes of vaccination would be effective.

Given that CPIV primarily enters the canine system through the mucosa, the World Small Animal Veterinary Association and American Animal Hospital Association vaccination guidelines suggest using the intranasal vaccine, as it may provide superior protection.<sup>15,16</sup> Mucosal vaccination also has the added advantages of not being subject to interference from maternally derived antibodies in younger animals and being able to provide a fairly rapid onset of immunity from stimulation of the innate immune response.<sup>10,16</sup> In one of the few studies comparing intranasal and parenteral CPIV vaccines, dogs vaccinated with the intranasal product had fewer postchallenge clinical signs. Moreover, viral shedding, which was 70% in control animals, was reduced to 50% in the parenteral vaccinates and to 1% in the intranasal vaccinates.<sup>17</sup>

Drawbacks to intranasal delivery include loss of vaccine when it is sneezed or snorted back out—a common occurrence—and potential danger to the person

**TABLE 2 Available Canine Parainfluenza Virus Vaccines<sup>a</sup>**

ORGANISMS IN VACCINE <sup>b</sup>	ROUTE OF ADMINISTRATION
Parainfluenza only	Parenteral
<i>Leptospira</i>	Parenteral
<i>Leptospira</i> , enteric coronavirus <sup>c</sup>	Parenteral
Distemper virus, adenovirus-2, parvovirus	Parenteral
Distemper virus, adenovirus-2, parvovirus, <i>Leptospira</i>	Parenteral
Distemper virus, adenovirus-2, parvovirus, <i>Leptospira</i> , enteric coronavirus <sup>c</sup>	Parenteral
<i>Bordetella bronchiseptica</i>	Intranasal
<i>Bordetella bronchiseptica</i> , adenovirus-2	Intranasal

<sup>a</sup>Only vaccines available in the United States and United Kingdom are listed.

<sup>b</sup>In addition to canine parainfluenza virus.

<sup>c</sup>Vaccination against enteric coronavirus is not recommended in the AAHA or WSAVA vaccination guidelines.

### Core or Noncore?

CPIV's effect on increasing the severity of illness caused by other respiratory pathogens may make it prudent to consider the parainfluenza vaccine "core" for dogs that are going to be social in any way. Before the use of available modified live vaccines, CPIV was isolated from up to 50% of dogs with respiratory symptoms in a group housing environment.<sup>6</sup> There is increasing evidence that intranasal vaccines are more effective at immunizing dogs and that dual-route vaccination (parenteral and intranasal) may provide even greater protection.<sup>9</sup> Annual vaccination in some form for CPIV may be something to consider as the role of coinfections in CIRD becomes more clear.

administering the vaccine to a fractious patient. The intranasal vaccines may cause transient side effects such as mild sneezing, coughing, or nasal discharge in a small percentage of dogs. These are signs that the innate immune response has been triggered by the vaccine.<sup>13,16</sup>

### Schedule of Vaccination

CPIV vaccination is considered noncore (only advised in animals at risk) and is advised to be started in puppies between 6 and 8 weeks of age.<sup>15,16</sup> If a parenteral vaccine is used, it should be given every 2 to 4 weeks until the puppy is 16 weeks old.<sup>14,15</sup> In adult dogs (older than 16 weeks), 1 dose or 2 doses given 2 to 4 weeks apart is advised. The parenteral CPIV vaccine is included in combination products that also contain the core vaccines against canine parvovirus, canine distemper virus, and/or canine adenovirus type 2 and provides immunization against all included pathogens for at least 1 year.

When CPIV enters the body, it triggers both the mucosal and the systemic responses of the adaptive immune system.

Intranasal products can be started in puppies as young as 4 weeks old. This may be useful in group housing situations or other high-risk environments. A single intranasal dose is indicated for puppies and for adult dogs to provide immunization for 1 year.<sup>14,15</sup>

Dogs can safely receive both parenteral and intranasal vaccines against CPIV in the same vaccination visit. In theory, dogs vaccinated at the same time by 2 different routes may be better protected than those vaccinated with either route alone. Additionally, human evidence suggests that vaccination with both a parenteral and a mucosal vaccine may create the most robust immune response.<sup>9</sup> The response to natural CPIV infection and vaccination is nonsterilizing, so titers cannot be used to determine the need for revaccination.<sup>16,18</sup>

### COMMUNICATION WITH CLIENTS

It is important that veterinarians educate clients about the significance of CIRD and the need to vaccinate against the causative agents with available vaccines. In at-risk animals, the dangers of coinfection and increased severity of disease are important reasons to vaccinate against pathogens that alone may not seem very significant. Many dogs resent intranasal vaccination, so it is also important for veterinarians to be complete and clear about the benefits of intranasal CPIV vaccination to ensure owner compliance. Additionally, it must be stressed that vaccination is a major part of a multifactorial disease prevention strategy.

### CONCLUSION

A growing number of pathogens contribute to the CIRD complex. While CPIV is historically considered a primary pathogen in this disease, its singular impact and clinical signs are not severe. However, when CPIV interacts with other pathogens, particularly in young or immunocompromised dogs, its impact becomes significant. Routine use of available vaccines helps reduce the role that CPIV plays in coinfection with a growing number of pathogens, thereby keeping at-risk dogs and populations healthier. **TVP**

### References

1. Ford RB. Canine infectious respiratory disease. In: Sykes J, Greene C, eds. *Infectious Diseases of the Dog and Cat*. 4<sup>th</sup> ed. St. Louis, MO: Saunders Elsevier, Inc; 2013:55-56.
2. Decaro N, Mari V, Larocca V, et al. Molecular surveillance of traditional and emerging pathogens associated with canine infectious respiratory disease. *Vet Microbiol*. 2016;192:21-25. doi: 10.1016/j.jvetmic.2016.06.009

3. Ellis JA, Krakowa GS. A review of canine parainfluenza virus infection in dogs. *JAVMA*. 2012;240(3):273-284.
4. Buonavoglia C, Martella V. Canine respiratory viruses. *Vet Res*. 2007;38(2):355-373. doi: 10.1051/vetres:2006058
5. Sykes JE. Canine viral respiratory infections. In: Sykes JE, ed. *Canine and Feline Infectious Diseases*. St. Louis, MO: W.B. Saunders; 2014:170-181.
6. McCandlish I, Thompson H, Cornwell H, Wright NG. A study of dogs with kennel cough. *Vet Rec*. 1978;102(14):293-301. doi: 10.1136/vr.102.14.293
7. Reagan KL, Skyes JE. Canine infectious respiratory disease. *Vet Clin North Am Small Anim Pract*. 2020;50(2):405-418. doi: 10.1016/j.cvs.2019.10.009
8. Maboni G, Seguel M, Lorton A, et al. Canine infectious respiratory disease: New insights into the etiology and epidemiology of associated pathogens. *PLoS One*. 2019;14(4):e0215817. doi: 10.1371/journal.pone.0215817
9. Mitchell JA, Cardwell JM, Leach H, et al. European surveillance of emerging pathogens associated with canine infectious respiratory disease. *Vet Microbiol*. 2017;212:31-38. doi: 10.1016/j.vetmic.2017.10.019
10. Tizard IR. The administration of vaccines. In: Tizard IR, ed. *Vaccines for Veterinarians*. St. Louis, MO: Elsevier Inc; 2021:113-115.
11. The Trust for Public Land. Dog park rankings for the 100 largest U.S. cities, 2019. [tplt.org/sites/default/files/City%20Park%20Facts%20Dog%20Parks%202019\\_R4.pdf](https://tplt.org/sites/default/files/City%20Park%20Facts%20Dog%20Parks%202019_R4.pdf). Accessed November 27, 2020.
12. Jacobs AA, Theelen RP, Jaspers R, et al. Protection of dogs for 13 months against *Bordetella bronchiseptica* and canine parainfluenza virus with a modified live vaccine. *Vet Rec*. 2005;157(1):19-23. doi: 10.1136/vr.157.1.19
13. Tizard IR. Canine vaccines. In: Tizard IR, ed. *Vaccines for Veterinarians*. St. Louis, MO: Elsevier Inc; 2021:182-183.
14. Ellis JA, Krakowa GS, Dayton AD, Konoby C. Comparative efficacy of an injectable vaccine and an intranasal vaccine in stimulating *Bordetella bronchiseptica*-reactive antibody responses in seropositive dogs. *JAVMA*. 2002;220(1):43-48. doi: 10.2460/javma.2002.220.43
15. Day MJ, Horzinek MC, Shultz RD, et al. WSAVA guidelines for the vaccination of dogs and cats. *J Small Anim Pract*. 2016;57(1):1-45. doi: 10.1111/jsap.13125
16. Ford RB, Larson LJ, McClure KD, et al. 2017 AAHA canine vaccination guidelines. *JAAHA*. 2017;53(5):243-251. doi: 10.5326/JAAHA-MS-6741
17. Kontor EJ, Wegrzyn RJ, Goodnow RA. Canine infectious tracheobronchitis: Effects of an intranasal live canine parainfluenza-*Bordetella bronchiseptica* vaccine on viral shedding and clinical tracheobronchitis (kennel cough). *Am J Vet Res*. 1981;42(10):1694-1698.
18. Ellis J, Anseeuw E, Gow S, et al. Seroepidemiology of respiratory (group 2) canine coronavirus, canine parainfluenza virus, and *Bordetella bronchiseptica* infections in urban dogs in a humane shelter and in rural dogs in small communities. *Can Vet J*. 2011;52(8):861-868.

## Amy E. S. Stone

Dr. Stone is a clinical assistant professor at the University of Florida's College of Veterinary Medicine (UFCVM). Since 2006, she has served as chief of the Primary Care and Dentistry Service at UFCVM's Small Animal Hospital. She serves on the AAHA/AAFP Feline Vaccination Task Force and is a contributing reviewer for the AAHA Canine Vaccination Guidelines. She received her DVM and PhD from the University of Florida. Her PhD focus was in pulmonary immunology, and her postdoctoral research involved work on a human periodontal disease vaccine.



### **KBroVet® -CA1 (potassium bromide chewable tablets)**

For complete prescribing information, see full package insert. **Caution:** Federal (US) law restricts this drug to use by or on the order of a licensed veterinarian. It is a violation of Federal Law to use this product other than as directed in the labeling. **Indication:** for the control of seizures associated with idiopathic epilepsy in dogs. **Warnings:** Not for human use. Keep out of reach of children. Contact a physician in case of accidental ingestion by humans. KBroVet-CA1 should not be used in animals with a history of hypersensitivity to bromide or any of the components of the tablets. Not for use in cats. Keep tablets in a secured location out of reach of dogs, cats, and other animals to prevent accidental ingestion or overdose. **Precautions:** The safe use of KBroVet-CA1 Chewable Tablets has not been evaluated in dogs that are intended for breeding, that are pregnant or lactating, or less than 6 months of age. Reproductive effects of potassium bromide (KBr) have been reported in other species. In dogs, ataxia, diarrhea, hematochezia, excessive salivation, shivering, skin lesions, stupor progressing to coma, and death have been reported with high doses.<sup>3,4</sup> Dogs receiving KBr should be carefully monitored when changing diets, administering chloride-containing IV fluids, and administering concurrent medications. Careful monitoring is important in dogs that have a condition that may cause difficulty maintaining electrolyte balance. Animals with decreased renal function may be predisposed to bromide toxicosis. Some dogs may experience epileptic episodes that are unresponsive or refractory to KBr monotherapy and KBr alone may not be adequate treatment for every dog with idiopathic epilepsy. **Adverse Reactions:** In a retrospective field of study of 51 dogs diagnosed with idiopathic epilepsy and treated with KBr, the most common clinical abnormalities documented in the 60 day period after start of KBr therapy were increased appetite, weight gain, vomiting/regurgitation and sedation. Additional field reports of clinical abnormalities in dogs dosed with KBr for idiopathic epilepsy showed polyphagia, polyuria, polydipsia, weight gain, lethargy and decreased physical activity. Ataxia was the most common body-system (i.e. CNS) specific clinical finding. Adverse events associated with concurrent use of KBr with other antiepileptic drugs such as phenobarbital have been reported, including sedation, irritability, restlessness, depression, behavioral changes, ataxia, hind limb paresis, mydriasis, stupor, and coma. These neurologic signs were reported to be reversible.<sup>2,3</sup> **Reasonable Expectation of Effectiveness:** This drug is conditionally approved pending a full demonstration of effectiveness. In a dose determination retrospective study involving a total of 284 canine case records, the mean total oral dose was determined to be 46.6 (±21.9) mg/kg/day with a range of 24.5-68.3 mg/kg/day, describing the range to achieve serum bromide concentrations within 10% of the published therapeutic range for dogs with idiopathic epilepsy. In a pilot retrospective study spanning a 5.7 year period, involving the review of case records of 51 client-owned dogs contributed by 18 veterinarians, and comparing the 30 day period before initial treatment with KBr and the 30 day period of steady state KBr dosing, 27 cases were determined as valid for evaluation of effectiveness. The mean maintenance dose in those 27 cases was 37 mg/kg/day, with a mean duration of 286 days. Approximately 67% of those cases were dosed once daily and 33% were dosed twice daily. Based on seizure count results, 70% of the 27 cases were defined as "success" and 30% were defined as "failures." Based on seizure event day results, 67% were defined as "success" and 33% were defined as "failures." Seizure severity score decreased or did not change in 25 of the 27 cases evaluated for effectiveness. Overall, of the 27 dogs included in the effectiveness analysis, 67% were considered treatment successes and 33% were considered treatment failures. **To obtain full product information please call 800-874-9764 or visit KBroVet.com.**

**Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-544.**

#### **Pegasus Laboratories, Inc.**

1. Podell, M., & Fenner, W. R. (1993). Bromide therapy in refractory canine idiopathic epilepsy. *Journal of Veterinary Internal Medicine*, 7(5), 318-327.
2. Boothe, D. M., Dewey, C., & Carpenter, D. M. (2012). Comparison of phenobarbital with bromide as a first-choice antiepileptic drug for treatment of epilepsy in dogs. *Journal of the American Veterinary Medical Association*, 240(9), 1073-1083.
3. Baird-Heinz, H. E., Van Schoick, A. N. L., Pelsor, F. R., Ranivand, L., & Hungerford, L. L. (2012). A systematic review of the safety of potassium bromide in dogs. *Journal of the American Veterinary Medical Association*, 240(6), 705-715.
4. Nichols, E. S., Trepanier, L. A., & Linn, K. (1996). Bromide toxicosis secondary to renal insufficiency in an epileptic dog. *Journal of the American Veterinary Medical Association*, 208(2), 231-233.

**Dosage and Administration:** For use in dogs only. The total recommended daily dosage range for KBroVet Chewable Tablets is 25-68 mg/kg, dosed with or without food, and should be adjusted based on monitoring of clinical response of the individual patient.<sup>1</sup> Use of an initial loading dosage regimen may be considered on an individual patient basis, balancing the time required to achieve a therapeutic response while minimizing side effects.<sup>2</sup> **Storage:** Store at 20-25°C (68-77°F). **WARNINGS: NOT FOR USE IN HUMANS. KEEP THIS AND ALL DRUGS OUT OF REACH OF CHILDREN.**